Home Tags IMGN632

Tag: IMGN632

ImmunoGen to Prioritize Continued Development of Mirvetuximab Soravtansine

Waltham, Massachusetts, based ImmunoGen, expanding field of antibody-drug conjugates (ADCs) with the development of the next generation of targeted anti-cancer agents, has completed an...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

Amid Significant Progress, Robust Growth and Advancing Pipeline — Immunogen Closes...

A leader in the expanding field of antibody-drug conjugates or ADCs for the treatment of cancer, Immunogen last week highlighted some of the company's...

Antibody-Drug Conjugates at the 59th American Society of Hematology Annual...

This year, in Atlanta, the South's largest and most vibrant city, the 59th annual meeting and exposition of the American Society of Hematology, to...

Jazz Pharmaceuticals and ImmunoGen Sign Development and Commercialization Agreement

Jazz Pharmaceuticals, an international biopharmaceutical company focusing on address unmet medical needs and ImmunoGen, a clinical-stage biotechnology company developing targeted cancer therapeutics using its proprietary antibody-drug conjugate...

IMGN632, a Novel CD123-Targeting Antibody-drug Conjugate, Demonstrates Activity in Acute Myeloid...

Preclinical data on IMGN632, a novel CD123-targeting antibody-drug conjugate being developed by ImmunoGen, presented at the 58th American Society of Hematology (ASH) Annual Meeting...

ASH 2016: Informative and Clinical Useful

Each year, ahead of key annual medical society meetings we ask the same question: What to expect during the upcoming meeting.  Are we going...